Kun for helsepersonell

Søk 

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss
OmAlopecia AreataLITFULO virkningsmekanismeSALT EvalueringEffektALLEGRO-2b/3 studieoversiktHårrespons i hodebunnenPasientrapporterte utfallØyenbryn og vipperesponsFør og etter bilderSikkerhetALLEGRO-2b/3 bivirkningerSamlede sikkerhetsdataYtterligere sikkerhetsinformasjonKom i gangDoseringScreening og oppfølgingSette pasientmålPasientprofilerOpplæringsmateriellMateriellVideo
Pasientrapporterte utfall

Week 24

Week 48

Tab Number 3

Tab Number 4

Tab Number 5

At Week 24, significantly more patients reported “greatly” or “moderately” improved alopecia areata with LITFULO vs placebo1‐3 Response is based on the Patient’s Global Impression of Change (PGI-C).*†‡ ReferencesPGI-C is a self-administered questionnaire that asks patients to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study. Responses of “moderately” or “greatly” improved were used as the 
patient-driven responder definition. Multiple imputation methods were based on generalised linear mixed model for longitudinal binary data up to Week 24 with an assumption of "missing at random" for SALT scores missing at Week 24 due to COVID-19. Patients with missing SALT scores due to other reasons were included in the analysis as nonresponders. A single complete imputed data set for Week 24 was analysed using the Miettinen and Nurminen method.The PGI-C response at Week 24 (key secondary endpoint for EMA) with LITFULO was statistically significant vs placebo (P<0.0001) with adjustment for multiplicity and based on a preestablished testing procedure for the EMA at an overall significance level (α=0.01). See how LITFULO helped with eyebrow and eyelash regrowth for patients with severe alopecia areata Øyenbryn- og øyenvipperesponsLoading

EMA=European Medicines Agency; SALT=Severity of Alopecia Tool.

References:1. LITFULO (ritlecitinib) Summary of Product Characteristics. 2. King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2. Erratum in: Lancet. 2023 Jun 10; 401(10392):1928. 3. King B, Zhang X, Harcha WG, et al. Supplement to: Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. April 13, 2023. doi:10.1016/S0140-6736(23)00222-2
PP-LGF-NOR-0019 | Utarbeidet 08.2024
More patients reported “greatly” or “moderately” improved alopecia areata with LITFULO vs placebo at Week 24, and continued through Week 481‐3 Response is based on the Patient’s Global Impression of Change (PGI-C).*†

Results after Week 24 through Week 48 were not placebo-controlled and were not adjusted for multiplicity.2

ReferencesPGI-C is a self-administered questionnaire that asks patients to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study. Responses of “moderately” or “greatly” improved were used as the patient-driven responder definition.Data missing due to COVID-19 were excluded, whereas patients with missing data due to other reasons were included as nonresponders. See how LITFULO helped with eyebrow and eyelash regrowth for patients with severe alopecia areata Øyenbryn- og øyenvipperesponsLoadingReferences:1. LITFULO (ritlecitinib) Summary of Product Characteristics. 2. King B, Zhang X, Harcha WG, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. 2023;401(10387):1518-1529. doi:10.1016/S0140-6736(23)00222-2. Erratum in: Lancet. 2023 Jun 10; 401(10392):1928. 3. King B, Zhang X, Harcha WG, et al. Supplement to: Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. Lancet. April 13, 2023. doi:10.1016/S0140-6736(23)00222-2.

     
PP-LGF-NOR-0019 | Utarbeidet 08.2024
Effekt Explore safety data SikkerhetLoading Get appropriate patients started on LITFULO today Kom i gangLoading

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 
Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei